



## Probiotics for Colic—Is the Gut Responsible for Infant Crying After All?

“Colic” is a term coined by the ancient Greeks centuries ago, derived from “kolikos,” meaning crampy pain, sharing its root with the word colon. For more than one-half of a century, researchers have tried to prove the condition to be related to the gut, and have failed to do so. That is, perhaps, until this last decade, with a sudden explosion of studies indicating gut microbiota, inflammation, and the gut-brain axis may play a part. The role of the probiotic *Lactobacillus reuteri* DSM17938 in infant colic has recently come under intense scrutiny. The study by Fatheree et al<sup>1</sup> in this volume of *The Journal* adds to this increasing and fascinating pool of evidence.

See related article, p 170

Since 1994, there have been at least a dozen case-control studies that have indicated differences in the gut microbiota between infants with and without colic. Some studies have indicated infants with colic to be less frequently colonized or have different colonization patterns of *Lactobacillus* species than those without colic.<sup>2-5</sup> At least 4 teams have indicated infants with colic to have more gram-negative organisms like *Escherichia* than those without colic.<sup>3,5-9</sup> One cross-sectional and 2 case-control studies indicated *Bifidobacterium* to be protective against crying.<sup>3,10,11</sup> *Helicobacter pylori* and *Clostridium difficile* have also been found in higher proportions in infants with colic than those without.<sup>12-14</sup> The underlying mechanisms of altered gut microbiota in infant crying are yet to be proven, but a possible pathway is through gut inflammation. Calprotectin is a gut inflammatory marker that has been shown to be increased in inflammatory bowel disease, cow’s milk protein allergy, celiac disease, necrotizing enterocolitis, and intestinal cystic fibrosis.<sup>15-18</sup> Rhoads et al<sup>7</sup> demonstrated that infants with colic had double the fecal calprotectin levels than those without colic, although another larger study did not find any difference in fecal calprotectin levels between infants with and without colic.<sup>19</sup> Partty et al<sup>20</sup> even suggested infants with colic to have low-grade systemic inflammation, indicated by increased levels of cytokines (interleukin-8 [IL-8]), chemokines monocyte chemoattractant protein and macrophage inflammatory protein 1beta in cases compared with controls.

One hypothesis is that probiotics may play a role in infant colic by altering gut microbiota, reducing gut inflammation and thereby reduce crying. *L reuteri* DSM17938 is the best studied strain, with 3 double-blind, placebo-controlled randomized trials in Italy, Poland, and Canada,<sup>21-23</sup> 1 single-blind trial in China,<sup>24</sup> and 1 open-label trial in Pakistan<sup>25</sup> concluding it to be effective at the dose of  $1 \times 10^8$  colony forming units in breastfed infants with colic. Sample sizes for these positive trials ranged from 42 to 80 infants. In contrast, the largest and only double-blind, randomized trial that included both breastfed and formula-fed infants with colic ( $n = 167$ ) in Australia was ineffective.<sup>26</sup> Interestingly, the US study by Fatheree et al, although very small in comparison, adds to this literature, being the second double-blind, randomized, placebo-controlled trial of *L reuteri* DSM17938 shown

to be ineffective in breastfed infants with colic. The study’s strengths include recruitment of a well-phenotyped group of infants with colic, use of a validated measure of infant crying and fussing, and detailed laboratory measures including blood and fecal samples. Unfortunately, the final sample size was small ( $n = 20$ ), significantly below the target sample size of 45 to detect group differences in adverse effects of sepsis and fever, and well below the sample size required to detect group differences in infant crying. Therefore, its conclusions must be interpreted with caution.

Nevertheless, the study reignites the hypothesis that gut inflammation may underlie infant colic. It is the first study to document neutropenia and thrombocytosis in infants with colic, and also the first to document increased fecal calprotectin levels that decrease with reduced crying. Interestingly, the study did not find evidence of systemic inflammation in these infants, unlike the study by Partty et al,<sup>20</sup> indicating that infants with colic have increased laboratory indicators of mild systemic inflammation compared with controls. It is possible that the documented levels of low neutrophil count, high platelet count, and high fecal calprotectin levels may be reflections of normal levels in healthy young infants, which change over time. Platelet and fecal calprotectin levels are higher in neonates as compared with older children, and there is no consensus for “normal cutpoint” levels for fecal calprotectin in infants.<sup>27-31</sup> Direct comparison of neutrophil, platelet, and fecal calprotectin levels in this cohort of infants with colic with healthy controls would be able to clarify this issue.

Like so many previous studies, *Escherichia* was the most frequently identified family of gut organisms in this study’s infants with colic, adding to the evidence that the presence of gram-negative organisms in the gut may contribute to crying. However, the proportion of gut *Escherichia* did not correlate with crying time, and in fact increased with resolution of colic in the majority of infants. Interestingly, the proportion of gut *Bacterioides* increased with reduction in crying, a finding that is similar to the *L reuteri* trial by Savino et al, where responders were found to be more frequently colonized by *Bacteroides* species.<sup>32</sup>

Although underpowered, this is the second negative *L reuteri* DSM17938 trial for infant colic treatment. Interestingly, like

V.S. is supported by a National Health and Medical Research Council Early Career Fellowship (APP1125687), a Royal Australasian College of Physicians Cottrell Research Establishment Fellowship, and has been supported by a Melbourne Children’s Clinician Scientist Fellowship. The Murdoch Children’s Research Institute is supported by the Victorian Government’s Operational Infrastructure Support Program. V.S. has served as a paid consultant for Mead Johnson Nutricionales de Mexico. M.C. has served as a paid consultant and speaker for Biogaia AB, served as a paid consultant for Nestle, and is an Editorial Board Member for *The Journal of Pediatrics*.

0022-3476/\$ - see front matter. © 2017 Elsevier Inc. All rights reserved.  
<https://doi.org/10.1016/j.jpeds.2017.09.010>

the negative Australian trial, it included a significant proportion of infants on antireflux medications. It is possible that these medications may alter the gut microbiota composition or dampen the way the gut responds to the administration of *L reuteri* DSM17938. However, it is to be noted that, in the Australian trial, both the probiotic and placebo groups had an equal proportion of infants on antireflux medications,<sup>26</sup> and moreover, antireflux medications have been demonstrated to be ineffective in reducing crying.<sup>33-37</sup>

Despite the limitation of its small sample size, the study by Fatheree et al sheds further light on the possible role of the gut microbiota, gut inflammation and the gut-brain-axis in infant colic. Whether these findings represent the cause or consequence of infant colic is difficult to untangle. Perhaps, it is true that infant colic is related to the gut after all and the ancient Greeks seem to have had the correct “gut feeling” all along. ■

**Valerie Sung, MBBS(Hons), FRACP, MPH, PhD**  
Murdoch Children’s Research Institute  
Royal Children’s Hospital  
University of Melbourne  
Parkville, Victoria, Australia

**Michael D. Cabana, MD, MPH**  
University of California, San Francisco  
San Francisco, California

Reprint requests: Valerie Sung, MBBS(Hons), FRACP, MPH, PhD, Royal Children’s Hospital, 50 Flemington Rd, Parkville, VIC 3052, Australia. E-mail: valerie.sung@rch.org.au

## References

- Fatheree NY, Liu Y, Taylor CM, Hoang TK, Cai C, Rahbar MH, et al. Lactobacillus reuteri for infants with colic: a double-blind, placebo-controlled, randomized clinical trial. *J Pediatr* 2017;191:170-8.
- Akbarian-Rad Z, Zahedpasha Y, Ahmadvpour-Kacho M, Rajabnia R, Tohidi F, Ferdosi-Shahandashti E. Intestinal Lactobacillus species: is it equal in colicky and non-colicky breastfed infants? *Iran J Neonatology* 2013;4:1-4.
- de Weerth C, Fuentes S, Puylaert P, de Vos WM. Intestinal microbiota of infants with colic: development and specific signatures. *Pediatrics* 2013;131:e550-8.
- Savino F, Bailo E, Oggero R, Tullio V, Roana J, Carlone N, et al. Bacterial counts of intestinal Lactobacillus species in infants with colic. *Pediatr Allergy Immunol* 2005;16:72-5.
- Savino F, Cresi F, Pautasso S, Palumeri E, Tullio V, Roana J, et al. Intestinal microflora in breastfed colicky and non-colicky infants. *Acta Paediatr* 2004;93:825-9.
- Mentula S, Tuure T, Koskenala R, Korpela R, Kononen E. Microbial composition and fecal fermentation end products from colicky infants—a probiotic supplementation pilot. *Microb Ecol Health Dis* 2008;20:37-47.
- Rhoads JM, Fatheree NY, Norori J, Liu Y, Lucke JF, Tyson JE, et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. *J Pediatr* 2009;155:823-8, e821.
- Savino F, Cordisco L, Tarasco V, Locatelli E, Di Gioia D, Oggero R, et al. Antagonistic effect of Lactobacillus strains against gas-producing coliforms isolated from colicky infants. *BMC Microbiol* 2011;11:157.
- Savino F, Cordisco L, Tarasco V, Calabrese R, Palumeri E, Matteuzzi D. Molecular identification of coliform bacteria from colicky breastfed infants. *Acta Paediatr* 2009;98:1582-8.
- Partty A, Kalliomaki M, Endo A, Salminen S, Isolauri E. Compositional development of Bifidobacterium and Lactobacillus microbiota is linked with crying and fussing in early infancy. *PLoS ONE* 2012;7:e32495.
- Partty A, Lehtonen L, Kalliomaki M, Salminen S, Isolauri E. Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. *Pediatr Res* 2015;78:470-5.
- Ali AM. Helicobacter pylori and infantile colic. *Arch Pediatr Adolesc Med* 2012;166:648-50.
- Ali ASA, Borei MBM. Helicobacter pylori and Egyptian infantile colic. *J Egypt Soc Parasitol* 2013;43:327-32.
- Lehtonen L, Korvenranta H, Eerola E. Intestinal microflora in colicky and noncolicky infants: bacterial cultures and gas-liquid chromatography. *J Pediatr Gastroenterol Nutr* 1994;19:310-4.
- Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. *Inflamm Bowel Dis* 2006;12:524-34.
- Kostakis ID, Cholidou KG, Vaiopoulos AG, Vlachos IS, Perrea D, Vaos G. Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review. *Dig Dis Sci* 2013;58:309-19.
- Vaos G, Kostakis ID, Zavras N, Chatzemihael A. The role of calprotectin in pediatric disease. *Biomed Res Int* 2013;2013:542363.
- Baldassarre ME, Laforgia N, Fanelli M, Laneve A, Grosso R, Lifschitz C. Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. *J Pediatr* 2010;156:397-401.
- Olafsdottir E, Aksnes L, Fluge G, Berstad A. Fecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. *Acta Paediatr* 2002;91:45-50.
- Partty A, Kalliomaki M, Salminen S, Isolauri E. Infant colic is associated with low-grade systemic inflammation. *J Pediatr Gastroenterol Nutr* 2017;64:691-5.
- Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, et al. Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. *J Pediatr* 2015;166:74-8.
- Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, et al. Lactobacillus reuteri DSM 17 938 in infantile colic: a randomized, double-blind, placebo-controlled trial. *Pediatrics* 2010;126:e526-33.
- Szajewska H, Gyrzczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. *J Pediatr* 2013;162:257-62.
- Mi GL, Zhao L, Qiao DD, Kang WQ, Tang MQ, Xu JK. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. *Antonie Van Leeuwenhoek* 2015;107:1547-53.
- Ashraf MW, Ayaz SB, Ashraf MN, Matee S, Shoaib M. Probiotics are effective in alleviating infantile colic; results of a randomized controlled trial held at Benazir Bhutto hospital, Rawalpindi, Pakistan. *Rawal Med J* 2015;40:277-80.
- Sung V, Hiscok H, Tang MLK, Mensah FK, Nation ML, Satzke C, et al. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. *BMJ* 2014;348:g2107.
- Savino F, Castagno E, Calabrese R, Viola S, Oggero R, Miniero R. High fecal calprotectin levels in healthy, exclusively breast-fed infants. *Neonatology* 2010;97:299-304.
- Campeotto F, Butel MJ, Kalach N, Derriex S, Aubert-Jacquin C, Barbot L, et al. High fecal calprotectin concentrations in newborn infants. *Arch Dis Child Fetal Neonatal Ed* 2004;89:F353-5.
- Campeotto F, Baldassarre M, Butel MJ, Viallon V, Nganzali F, Soulaïnes P, et al. Fecal calprotectin: cutoff values for identifying intestinal

- distress in preterm infants. *J Pediatr Gastroenterol Nutr* 2009;48:507-10.
30. Rugtveit J, Fagerhol MK, Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. *J Pediatr Gastroenterol Nutr* 2002;34:323-4, author reply 324-5.
  31. Nissen AC, van Gils CE, Menheere PP, Van den Neucker AM, van der Hoeven MA, Forget PP. Fecal calprotectin in healthy term and preterm infants. *J Pediatr Gastroenterol Nutr* 2004;38:107-8.
  32. Roos S, Dicksved J, Tarasco V, Locatelli E, Ricceri F, Grandin U, et al. 454 pyrosequencing analysis on fecal samples from a randomized DBPC trial of colicky infants treated with *Lactobacillus reuteri* DSM 17938. *PLoS ONE* 2013;8:e56710.
  33. Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. *J Pediatr* 2003;143:219-23.
  34. Jordan B, Heine RG, Meehan M, Catto-Smith AG, Lubitz L. Effect of antireflux medication, placebo and infant mental health intervention on persistent crying: a randomized clinical trial. *J Paediatr Child Health* 2006;42:49-58.
  35. Loots C, Kritas S, Van Wijk M, McCall L, Peeters L, Lewindon P, et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. *J Pediatr Gastroenterol Nutr* 2014;59:237-43.
  36. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. *J Pediatr* 2009;154:514-20, e514.
  37. Gieruszczak-Białek D, Konarska Z, Skórka A, Vandenplas Y, Szajewska H. No effect of proton pump inhibitors on crying and irritability in infants: systematic review of randomized controlled trials. *J Pediatr* 2015;166:767-70, e763.

## Epilepsy by Any Other Name Would (Not!) Smell as Sweet



Shakespeare, in *Romeo and Juliet* (Act II, Scene II), implies that what something is called does not detract from its fundamental meaning or worth: “A rose by any other name would smell as sweet.” Juliet was expressing her love for Romeo, irrespective of his name (alas, he was a Montague!).

But in medicine, the importance of linguistic precision cannot be underestimated.<sup>1</sup> Although names (for diseases, conditions, symptoms, signs, etc) differ in various contexts, optimal medical care requires accurate communication between health care providers, patients, and families, and this accuracy begins with consistency in the use of words to communicate medical information. This challenge is nowhere more poignant than in epilepsy, a disorder still fraught with stigma worldwide<sup>2</sup> and with dismal public awareness,<sup>3</sup> in part owing to the way that we professionals use (and misuse) terminology. The recent evolution of nomenclature to define and classify seizures and epilepsy,<sup>4,6</sup> driven by rapid advances in our understanding of the pathophysiology, genetics, and imaging correlates of seizure generation and epileptogenesis, is making it hard enough for specialists to keep up, let alone patients and families!

How can a parent or other primary caregiver of a child with epilepsy be expected to understand the definition of the term if medical professionals lack a common language? Even some epilepsy experts are hesitant to use the word epilepsy, instead couching the disorder as a nonspecific phrase such as seizure disorder or some other euphemism.<sup>7</sup> Calling epilepsy a seizure disorder is akin to calling asthma a breathing disorder or Ewing sarcoma a cancer disorder—those terms lack specificity and provide no clinical detail, rendering them almost useless. Yet, the moniker seizure disorder continues to be used widely among physicians and even neurologists. Epilepsy is currently defined as: (1) at least 2 unprovoked (or reflex) seizures occurring more than 24 hours apart, or (2) 1 unprovoked (or reflex) seizure with at least a 60% chance of recurrence, or (3) a diagnosis of an epilepsy syndrome.<sup>4</sup>

Therefore, epilepsy certainly entails seizures, but it is so much more, especially in pediatric epilepsy, where syndromes often comprise a specific age range of onset, etiology, medication

responsiveness, genetic background, and natural history. There is an oft-told story of parents who expressed surprise and chagrin when it was mentioned that their child had epilepsy, whereas for years they had been told the child only had a seizure disorder; although apocryphal, this story exemplifies the need to communicate in the most accurate fashion from the outset. Otherwise, we are committing a disservice to patients and families who deserve an accurate diagnostic label to facilitate their own understanding of their child’s disorder as they navigate the medical system, seek support from disease advocacy organizations, and communicate with friends, relatives, friends, and the wider community.

How well do caregivers of children with epilepsy understand the terms used to describe this condition? The report by Nagan et al in this volume of *The Journal* is a valiant attempt to characterize and quantify parental understanding of the term epilepsy.<sup>8</sup> They hypothesize that parents have a poor understanding of the term. Through a carefully designed telephone survey, the investigators surveyed 45 caregivers whose children had been diagnosed with epilepsy. They inquired how well caregivers understood the definition of epilepsy in 3 ways. First, they asked whether their child had a seizure disorder, epilepsy, or both. Second, they asked the caregiver to define epilepsy, in an open-ended manner. Third, using a multiple-choice format, they asked parents to choose among 4 possible definitions of epilepsy. In addition, they obtained a sense of the caregivers’ own self-perceived understanding of epilepsy.

The results were discouraging, but not surprising. Their hypothesis was verified—very few caregivers correctly identified their children as having epilepsy or provided an accurate definition. A full one-third of respondents had no correct

See related article, p 197

The author declares no conflicts of interest.

0022-3476/\$ - see front matter. © 2017 Elsevier Inc. All rights reserved.  
<https://doi.org/10.1016/j.jpeds.2017.09.005>